Rejuveron Life Sciences AG Becomes Centenara Labs AG, Shares Clinical Updates

Centenara Labs AG ("Centenara"), previously known as Rejuveron Life Sciences AG, has announced a strategic rebranding initiative following shareholder approval at their Extraordinary General Meeting on August 23, 2024. This Zurich-based biotechnology firm is committed to developing therapies that promote healthy aging, with a focus on regenerative medicine and age-related disorders.

The company's new name, Centenara Labs AG, reflects its mission to help individuals maintain functional independence, physical and mental fitness, and sensory abilities throughout their lives. This rebranding effort aims to differentiate Centenara in the competitive biotechnology market, enhance public awareness, and position the company for future growth. The name "Centenara" is inspired by the goal of improving the quality of life, akin to that experienced by centenarians.

CEO Aksana Labokha emphasized that the rebranding symbolizes more than just a name change; it signifies a renewed focus on developing therapies for regenerative medicine and age-related conditions. The updated visual identity is designed to highlight Centenara's evolution within the biotechnology sector, emphasizing their commitment to extending quality of life through innovative therapies. Additionally, the rebranding is expected to support strategic goals such as exploring public market opportunities and potential pharmaceutical partnerships, while advancing a pipeline of breakthrough therapeutics targeting the hallmarks of aging.

Centenara's research and development efforts are currently centered on transforming promising discoveries in ophthalmology and senescence research into innovative therapies that promote independence and well-being. The company encourages investors and interested parties to visit their updated website for more information.

In line with their rebranding, Centenara has provided an update on the EA-2353 program, a treatment for Retinitis Pigmentosa (RP). RP is a rare, inherited retinal disease that leads to progressive vision loss, with most patients becoming legally blind by age 40. EA-2353, a small molecule endogenous stem cell treatment, aims to preserve or restore visual function by activating dormant retinal stem and progenitor cells. Preliminary results from a Phase 1/2a clinical trial indicated that EA-2353 was safe and well-tolerated, showing positive trends in visual function and retinal sensitivity.

RP currently lacks effective treatment options for many patients, making EA-2353 a promising gene-independent approach that offers significant advantages due to the multiple genetic causes of RP. The U.S. Food and Drug Administration granted orphan drug designation to EA-2353 in May 2021.

Centenara is a clinical-stage biotechnology company dedicated to developing therapies that foster healthy aging. Their team of experienced scientists leverages a deep understanding of aging biology and advances in biopharmaceutical research to create innovative medicines. Centenara's therapeutic pipeline spans various stages of drug development, focusing on preventing, repairing, or reversing the hallmarks of aging.

The current product portfolio includes a range of therapies targeting different age-related conditions. These include treatments for dry age-related macular degeneration in the pre-clinical phase, novel therapies for diseases associated with fibrosis and cancer due to cellular senescence, a telomere program aimed at reversing telomere damage, and treatments for neurodegenerative and cognitive disorders. Centenara was co-founded in 2019 by scientist Matthias Steger and investor Christian Angermayer. Under the leadership of CEO Aksana Labokha, Centenara continues to push the boundaries of biotechnology to improve the quality of life as individuals age.